NASDAQ:ENVB

Enveric Biosciences Competitors

$2.38

+0.01 (+0.42 %)

(As of 04/16/2021 12:00 AM ET)

Add

Compare

Today's Range

$2.20

Now: $2.38▼

$2.39

50-Day Range

$2.37

MA: $3.22▼

$4.54

52-Week Range

$2.33

Now: $2.38▼

$21.20

Volume853,779 shs

Average Volume6.31 million shs

Market Capitalization$46.29 million

P/E RatioN/A

Dividend YieldN/A

Beta1.81

Enveric Biosciences (NASDAQ:ENVB) Vs. PXLW, GSIT, SPI, MRAM, QUIK, and LPTH

Should you be buying ENVB stock or one of its competitors? Companies in the industry of "semiconductors & related devices" are considered alternatives and competitors to Enveric Biosciences, including Pixelworks (PXLW), GSI Technology (GSIT), SPI Energy (SPI), Everspin Technologies (MRAM), QuickLogic (QUIK), and LightPath Technologies (LPTH).

Enveric Biosciences vs. Pixelworks Stock

Pixelworks (NASDAQ:PXLW) and Enveric Biosciences (NASDAQ:ENVB) are both small-cap computer and technology companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, analyst recommendations, risk, institutional ownership, profitability and earnings.

Insider and Institutional Ownership

33.8% of Pixelworks shares are held by institutional investors. Comparatively, 0.8% of Enveric Biosciences shares are held by institutional investors. 4.6% of Pixelworks shares are held by company insiders. Comparatively, 4.4% of Enveric Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of recent ratings for Pixelworks and Enveric Biosciences, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pixelworks	0	1	2	0	2.67
Enveric Biosciences	0	0	0	0	N/A

Pixelworks currently has a consensus target price of $5.0833, indicating a potential upside of 59.85%. Given Pixelworks' higher possible upside, equities research analysts clearly believe Pixelworks is more favorable than Enveric Biosciences.

Profitability

This table compares Pixelworks and Enveric Biosciences' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Pixelworks	-51.96%	-31.06%	-20.07%
Enveric Biosciences	-19.34%	-58.42%	-25.44%

Volatility & Risk

Pixelworks has a beta of 2.21, indicating that its stock price is 121% more volatile than the S&P 500. Comparatively, Enveric Biosciences has a beta of 1.81, indicating that its stock price is 81% more volatile than the S&P 500.

Valuation and Earnings

This table compares Pixelworks and Enveric Biosciences' gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pixelworks	$68.75 million	2.42	$-9,080,000.00	($0.12)	-26.50
Enveric Biosciences	$39.92 million	1.16	$-5,600,000.00	N/A	N/A

Enveric Biosciences has lower revenue, but higher earnings than Pixelworks.

Summary

Pixelworks beats Enveric Biosciences on 9 of the 11 factors compared between the two stocks.

Enveric Biosciences vs. GSI Technology Stock

GSI Technology (NASDAQ:GSIT) and Enveric Biosciences (NASDAQ:ENVB) are both small-cap computer and technology companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, risk, profitability, institutional ownership and earnings.

Institutional and Insider Ownership

33.1% of GSI Technology shares are held by institutional investors. Comparatively, 0.8% of Enveric Biosciences shares are held by institutional investors. 35.3% of GSI Technology shares are held by company insiders. Comparatively, 4.4% of Enveric Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of recent recommendations and price targets for GSI Technology and Enveric Biosciences, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GSI Technology	0	1	0	0	2.00
Enveric Biosciences	0	0	0	0	N/A

Profitability

This table compares GSI Technology and Enveric Biosciences' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
GSI Technology	-61.99%	-22.69%	-19.86%
Enveric Biosciences	-19.34%	-58.42%	-25.44%

Volatility & Risk

GSI Technology has a beta of 0.88, indicating that its share price is 12% less volatile than the S&P 500. Comparatively, Enveric Biosciences has a beta of 1.81, indicating that its share price is 81% more volatile than the S&P 500.

Earnings & Valuation

This table compares GSI Technology and Enveric Biosciences' gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GSI Technology	$43.34 million	3.62	$-10,340,000.00	N/A	N/A
Enveric Biosciences	$39.92 million	1.16	$-5,600,000.00	N/A	N/A

Enveric Biosciences has lower revenue, but higher earnings than GSI Technology.

Summary

GSI Technology beats Enveric Biosciences on 6 of the 9 factors compared between the two stocks.

Enveric Biosciences vs. SPI Energy Stock

SPI Energy (NASDAQ:SPI) and Enveric Biosciences (NASDAQ:ENVB) are both small-cap oils/energy companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, risk, profitability, institutional ownership and earnings.

Institutional and Insider Ownership

6.3% of SPI Energy shares are held by institutional investors. Comparatively, 0.8% of Enveric Biosciences shares are held by institutional investors. 4.4% of Enveric Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of recent recommendations and price targets for SPI Energy and Enveric Biosciences, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SPI Energy	0	0	0	0	N/A
Enveric Biosciences	0	0	0	0	N/A

Profitability

This table compares SPI Energy and Enveric Biosciences' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
SPI Energy	N/A	N/A	N/A
Enveric Biosciences	-19.34%	-58.42%	-25.44%

Volatility & Risk

SPI Energy has a beta of 1.01, indicating that its share price is 1% more volatile than the S&P 500. Comparatively, Enveric Biosciences has a beta of 1.81, indicating that its share price is 81% more volatile than the S&P 500.

Earnings & Valuation

This table compares SPI Energy and Enveric Biosciences' gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SPI Energy	$97.88 million	1.42	$-15,260,000.00	N/A	N/A
Enveric Biosciences	$39.92 million	1.16	$-5,600,000.00	N/A	N/A

Enveric Biosciences has lower revenue, but higher earnings than SPI Energy.

Summary

SPI Energy beats Enveric Biosciences on 6 of the 9 factors compared between the two stocks.

Enveric Biosciences vs. Everspin Technologies Stock

Everspin Technologies (NASDAQ:MRAM) and Enveric Biosciences (NASDAQ:ENVB) are both small-cap business services companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, risk, profitability, institutional ownership and earnings.

Profitability

This table compares Everspin Technologies and Enveric Biosciences' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Everspin Technologies	-24.00%	-44.04%	-24.46%
Enveric Biosciences	-19.34%	-58.42%	-25.44%

Analyst Ratings

This is a summary of recent recommendations and price targets for Everspin Technologies and Enveric Biosciences, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Everspin Technologies	0	0	1	0	3.00
Enveric Biosciences	0	0	0	0	N/A

Everspin Technologies currently has a consensus price target of $10.00, indicating a potential upside of 91.94%. Given Everspin Technologies' higher possible upside, analysts clearly believe Everspin Technologies is more favorable than Enveric Biosciences.

Earnings & Valuation

This table compares Everspin Technologies and Enveric Biosciences' gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Everspin Technologies	$37.50 million	2.67	$-14,670,000.00	($0.80)	-6.51
Enveric Biosciences	$39.92 million	1.16	$-5,600,000.00	N/A	N/A

Enveric Biosciences has higher revenue and earnings than Everspin Technologies.

Institutional and Insider Ownership

26.7% of Everspin Technologies shares are held by institutional investors. Comparatively, 0.8% of Enveric Biosciences shares are held by institutional investors. 23.6% of Everspin Technologies shares are held by company insiders. Comparatively, 4.4% of Enveric Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Volatility & Risk

Everspin Technologies has a beta of 1.65, indicating that its share price is 65% more volatile than the S&P 500. Comparatively, Enveric Biosciences has a beta of 1.81, indicating that its share price is 81% more volatile than the S&P 500.

Summary

Everspin Technologies beats Enveric Biosciences on 7 of the 11 factors compared between the two stocks.

Enveric Biosciences vs. QuickLogic Stock

Enveric Biosciences (NASDAQ:ENVB) and QuickLogic (NASDAQ:QUIK) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, profitability, earnings, risk, analyst recommendations, institutional ownership and dividends.

Profitability

This table compares Enveric Biosciences and QuickLogic's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Enveric Biosciences	-19.34%	-58.42%	-25.44%
QuickLogic	-125.18%	-78.90%	-31.56%

Analyst Recommendations

This is a breakdown of current ratings and price targets for Enveric Biosciences and QuickLogic, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enveric Biosciences	0	0	0	0	N/A
QuickLogic	0	1	1	0	2.50

QuickLogic has a consensus price target of $8.00, indicating a potential upside of 21.77%. Given QuickLogic's higher possible upside, analysts plainly believe QuickLogic is more favorable than Enveric Biosciences.

Valuation and Earnings

This table compares Enveric Biosciences and QuickLogic's revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enveric Biosciences	$39.92 million	1.16	$-5,600,000.00	N/A	N/A
QuickLogic	$10.31 million	7.18	$-15,440,000.00	($2.02)	-3.25

Enveric Biosciences has higher revenue and earnings than QuickLogic.

Insider & Institutional Ownership

0.8% of Enveric Biosciences shares are held by institutional investors. Comparatively, 26.1% of QuickLogic shares are held by institutional investors. 4.4% of Enveric Biosciences shares are held by insiders. Comparatively, 2.9% of QuickLogic shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Risk & Volatility

Enveric Biosciences has a beta of 1.81, suggesting that its share price is 81% more volatile than the S&P 500. Comparatively, QuickLogic has a beta of 1.99, suggesting that its share price is 99% more volatile than the S&P 500.

Summary

Enveric Biosciences beats QuickLogic on 6 of the 11 factors compared between the two stocks.

Enveric Biosciences vs. LightPath Technologies Stock

Enveric Biosciences (NASDAQ:ENVB) and LightPath Technologies (NASDAQ:LPTH) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, profitability, earnings, risk, analyst recommendations, institutional ownership and dividends.

Profitability

This table compares Enveric Biosciences and LightPath Technologies' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Enveric Biosciences	-19.34%	-58.42%	-25.44%
LightPath Technologies	6.33%	7.46%	5.42%

Analyst Recommendations

This is a breakdown of current ratings and price targets for Enveric Biosciences and LightPath Technologies, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enveric Biosciences	0	0	0	0	N/A
LightPath Technologies	0	0	3	0	3.00

LightPath Technologies has a consensus price target of $5.1667, indicating a potential upside of 90.65%. Given LightPath Technologies' higher possible upside, analysts plainly believe LightPath Technologies is more favorable than Enveric Biosciences.

Valuation and Earnings

This table compares Enveric Biosciences and LightPath Technologies' revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enveric Biosciences	$39.92 million	1.16	$-5,600,000.00	N/A	N/A
LightPath Technologies	$34.97 million	2.03	$870,000.00	$0.03	90.33

LightPath Technologies has lower revenue, but higher earnings than Enveric Biosciences.

Insider & Institutional Ownership

0.8% of Enveric Biosciences shares are held by institutional investors. Comparatively, 24.3% of LightPath Technologies shares are held by institutional investors. 4.4% of Enveric Biosciences shares are held by insiders. Comparatively, 11.5% of LightPath Technologies shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Risk & Volatility

Enveric Biosciences has a beta of 1.81, suggesting that its share price is 81% more volatile than the S&P 500. Comparatively, LightPath Technologies has a beta of 1.44, suggesting that its share price is 44% more volatile than the S&P 500.

Summary

LightPath Technologies beats Enveric Biosciences on 9 of the 11 factors compared between the two stocks.